FIELD: biotechnology.
SUBSTANCE: what is described is a method for detecting Berezovsky-Reed-Sternberg cells (BRS) in lymph nodes of patients with classical Hodgkin's lymphoma. Method involves analysing a biopsy material of lymph nodes of patients with suspected cHL and preparing a cell suspension by mechanical grinding of tissue in a buffer solution, followed by a direct immunofluorescence reaction. According to the invention method, markers CD40, CD95, CD45, CD15, CD64, CD19, CD30, CD20, CD3 combined into one sample, and after staining with monoclonal antibodies, the sample is analysed on 14-parameter high-resolution flow cytometer.
EFFECT: invention extends the range of methods for detecting BRS cells in lymph nodes of patients with classical Hodgkin's lymphoma.
1 cl, 1 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETECTING TUMOUR CELLS CIRCULATING IN BLOOD BY MULTIPARAMETER FLOW CYTOMETRY | 2024 |
|
RU2825188C2 |
| METHOD FOR PREDICTION OF EARLY RECURRENCE IN PATIENTS WITH CLASSICAL HODGKIN'S LYMPHOMA | 2019 |
|
RU2702360C1 |
| LABORATORY DIAGNOSTIC TECHNIQUE FOR PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA | 2015 |
|
RU2574968C1 |
| METHOD FOR DETERMINING MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER FLOW CYTOMETRY IN CHILDREN AND ADULTS WITH B-LINEAR ACUTE LYMPHOBLASTIC LEUKEMIA IN CONDITIONS OF CD19-DIRECTED IMMUNOTHERAPY | 2022 |
|
RU2818950C1 |
| METHODS OF OBTAINING CELLS, DEMONSTRATING PHENOTYPIC PLASTICITY | 2010 |
|
RU2536941C2 |
| SENTINEL LYMPH NODES DIAGNOSING METHOD IN GASTRIC CANCER | 2020 |
|
RU2727251C2 |
| METHOD FOR ESTIMATION OF BONE MARROW ASPIRATION QUALITY DURING MONITORING OF MINIMUM RESIDUAL DISEASE IN CASE OF MULTIPLE MYELOMA | 2016 |
|
RU2639382C1 |
| METHOD OF THE DIFFERENTIAL DIAGNOSIS OF ACUTE LEUKEMIA USING A CELLULAR BIOCHIP | 2017 |
|
RU2681651C1 |
| METHOD OF DETECTION OF CELL-FREE DNA IN WHOLE PERIPHERAL BLOOD USING FLOW CYTOMETRY | 2022 |
|
RU2815709C1 |
| METHOD OF ASSESSING MINIMAL RESIDUAL DISEASE (MRD) BY MULTICOLOR FLOW CYTOMETRY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN THE POST-INDUCTION PHASE OF TREATMENT | 2022 |
|
RU2802131C1 |
